• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Glucagon Receptor Antagonist–Stimulated α-Cell Proliferation Is Severely Restricted With Advanced Age

byConstance WuandAliya Ramjaun
May 17, 2019
in Chronic Disease, Endocrinology, Gastroenterology, Preclinical
Reading Time: 2 mins read
Share on FacebookShare on Twitter

Glucagon-containing α-cells are important for regulating glucose homeostasis along with insulin-secreting β-cells. Glucagon receptor antagonists (GRAs) hold potential as antidiabetic therapies, but there is a concern that GRAs may cause α-cells to proliferate. While studies evaluating this have been carried out in rodents, these have been limited to young mice, raising questions surrounding the effect of GRAs in adult mice and adult animals in general. In this controlled study, investigators gave a highly selective GRA (JNJ-46207382) to both young and adult mice in order to examine the effect of GRAs on measured α-cell turnover and proliferation. Investigators found that in young mice, the GRA caused a 2.5 fold greater α-cell proliferation. In adult mice, administration of the GRA also resulted in α-cell proliferation, but this proliferation was 60% less than what was observed in young mice. In both young and adult mice, pancreas mass was unaltered by the GRA studied, and islet histology was also normal. Taken together, the results from this study suggest that administration of GRA causes a greater degree of expansion of α-cells in young mice as compared to older mice. This has implications for potential GRA use in middle-aged or elderly patients who may have minimal α-cell proliferation. This study was limited, however, in that it used a single GRA molecule in a rodent model that may or may not be generalizable to humans. The mice used in this study were also non-diabetic, therefore, the effect of GRAs on diabetic α-cells requires further study.

Click to read the study in Diabetes

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

RELATED REPORTS

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

2 Minute Medicine Rewind June 29, 2026

Telehealth yields modest improvements in diabetes outcomes 

Tags: diabetesGlucagon receptor antagonists (GRA)insulin-secreting β-cellsα-cells
Previous Post

Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren

Next Post

Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage

RelatedReports

Cost-related medication nonadherence associated with increased ED utilization
Pharma

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

September 4, 2026
Weekly Rewinds

2 Minute Medicine Rewind June 29, 2026

June 29, 2026
Chronic Disease

Telehealth yields modest improvements in diabetes outcomes 

June 22, 2026
Food environment associated with gestational diabetes
Chronic Disease

Tirzepatide improves blood sugar control in metformin-refractory type 2 diabetes

May 25, 2026
Next Post
Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage

Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Quick Take: Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression

#VisualAbstract: Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome in Out-of-Hospital Cardiac Arrest

#VisualAbstract: Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome in Out-of-Hospital Cardiac Arrest

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Earlier Genetic Testing Predicts Bilateral Mastectomy in Young BRCA Carriers
  • Uterine-Sparing Mesh Repair Outperforms Hysterectomy for Prolapse
  • Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in